FDG
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 84 | サルコイドーシス | 8 |
84. サルコイドーシス
臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
Showing 1 to 8 of 8 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03705884 (ClinicalTrials.gov) | January 1, 201820180101 | 8/8/201820180808 | PET/MR Imaging In Patients With Cardiac Sarcoidosis | Molecular Imaging in Cardiovascular Disease Using Hybrid Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR): Cardiac Sarcoidosis Molecular Imaging in Cardiovascular Disease Using Hybrid Positron Emission Tomography/Magnetic Reson ... | Cardiac Sarcoidosis | Other: 18F-FDG;Drug: Prednisolone | University of Edinburgh | NULL | Unknown status | 40 Years | N/A | All | 40 | N/A | United Kingdom |
| 2 | NCT03048097 (ClinicalTrials.gov) | February 1, 201720170201 | 2/2/201720170202 | Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 | Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac Sarcoidosis Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfu ... | Sarcoidosis | Drug: Fluorodeoxyglucose;Drug: Rubidium;Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging Drug: Fluorodeoxyglucose;Drug: Rubidium;Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion I ... | Yale University | NULL | Completed | 18 Years | N/A | All | 15 | Early Phase 1 | United States |
| 3 | JPRN-jRCTs041180111 (jRCTs041180111) | 16/12/201620161216 | 19/03/201920190319 | Estimated by FDG PET/CT in Myocardial Sarcoidosis | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - OMT-CS study | Cardiac sarcoidosis Cardiac sarcoidosis | After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasing over 70%, PSL was prescribed 5mg/day for more 6 months. If TLG is decreasing under 70%, arm A: PSL was prescribed 30mg/day and diminishing PSL 5mg per month for more 6 months arm B: MTX (6mg/week) and folic acid (5mg/week) was prescribed for more 6 months After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasi ... | Murohara Toyoaki | NULL | Complete | >= 20age old | Not applicable | Both | 85 | Phase 3 | Japan |
| 4 | JPRN-UMIN000022996 | 2016/10/0820161008 | 04/07/201620160704 | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - Optimal Medical Therapy in Myocardial Sarcoidosis Optimal Medical Therapy Estimated by FDGPET/CT in Myocardial Sarcoidosis - Optimal Medical Therapy i ... | Myocardial sarcoidosis | mediacl therapy with methotrexate medical therapy with steroid | The Department of Cardiology, Nagoya University Graduate School of Medicine | NULL | Recruiting | 20years-old | 90years-old | Male and Female | 50 | Not selected | Japan |
| 5 | NCT02824419 (ClinicalTrials.gov) | May 201620160500 | 27/5/201620160527 | Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Imaging of Active Granulomas With [18F]FDGand Selected Inflammatory PET Tracers in Pulmonary Sarcoid ... | Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Imaging of Active Granulomas With [18F]FDGand Selected Inflammatory PET Tracers in Pulmonary Sarcoid ... | Pulmonary Sarcoidosis | Drug: Methionine;Drug: DOTANOC | Turku University Hospital | NULL | Recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | Finland |
| 6 | EUCTR2015-001815-11-FI (EUCTR) | 19/04/201620160419 | 29/12/201520151229 | PET imaging of pulmonary sarcoidosis | Imaging of active granulomas with [18F]FDG and selected inflammatory PET tracers in pulmonary sarcoidosis Imaging of active granulomas with [18F]FDGand selected inflammatory PET tracers in pulmonary sarcoid ... | Pulmonary sarcoidosis with active garnulomas in the lungs. The diagnosis is based on the clinical evidence or biopsy. MedDRA version: 18.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] Pulmonary sarcoidosis with active garnulomas in the lungs. The diagnosis is based on the clinical ev ... | Product Name: 18F-fluorodeoxyglucose Product Code: FDG INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE Product Name: C11-methionine INN or Proposed INN: L-methionine Other descriptive name: L-METHIONINE ([11C]METHYL) Product Name: 68Ga-DOTANOC INN or Proposed INN: DOTANOC Other descriptive name: DOTANOC Product Name: 18F-fluorodeoxyglucose Product Code: FDG INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLU ... | Turku PET Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Finland | ||||
| 7 | JPRN-UMIN000004267 | 2010/10/0120101001 | 01/10/201020101001 | PET/CT finding of cardiac sarcoidosis | PET/CT finding of cardiac sarcoidosis - PET/CT finding of cardiac sarcoidosis | sarcoidosis | Give heparin Na before 18F-FDG PET/CT in the diagnosis of cardial sarcoidosis. | Tokushima University Hospital | NULL | Pending | Not applicable | Not applicable | Male and Female | 30 | Not selected | Japan |
| 8 | JPRN-UMIN000006533 | 2010/04/0120100401 | 30/10/201120111030 | Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (H ... | Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects - Detecting sympathetic denervation and regional myocardial inflammation in patients with cardiac involvement sarcoidosis (CANVAS study) Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (H ... | sarcoidosis | All patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 11C HED PET/CT,18F FDG PET/CT, 15O-PET water, MIBG, 12 leads ECG, AECG , SAECG and echocardiogram (Echo) before starting corticosteroid therapy and repeat study at 4 weeks after starting corticosteroid therapy. These patients will also have reevaluation 6 to 12 month after the second evaluations. Sarcoidosis without cardiac involvement will undergo steroid treatment will also repeat the same measurements 4 weeks after the treatment. Cardiac sarcoidosis but will not have steroid treatment will also repeat the same measurements 12 months later. Sarcoidosis patients without steroid treatment will also repeat the same measurements 12 months later. Cardiac sarcoidosis with steroid treatment. Cardiac sarcoidosis without steroid treatment. arcoidosis without cardiac involvement who will have steroid treatement. Sarcoidosis without cardiac involvement who will not have steroid treatement. Normal control. All patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 1 ... | Hokkaido University Graduate School of Medicine | ,NULL | Recruiting | Not applicable | Not applicable | Male and Female | 50 | Not applicable | Japan |